CN Patent

CN105517541A — 包含阿曲生坦的稳定化药物剂型

Assigned to AbbVie Inc · Expires 2016-04-20 · 10y expired

What this patent protects

本公开涉及：(a)？包含阿曲生坦或其可药用盐和任选另一治疗剂的稳定化药物剂型；(b)？使用这样的药物剂型治疗肾病、慢性肾病和/或其它病况的方法；(c)？包含这样的药物剂型和任选含另一治疗剂的第二药物剂型的药盒；(d)？制备这样的药物剂型的方法；和(e)？通过这样的方法制成的药物剂型。

USPTO Abstract

本公开涉及：(a)？包含阿曲生坦或其可药用盐和任选另一治疗剂的稳定化药物剂型；(b)？使用这样的药物剂型治疗肾病、慢性肾病和/或其它病况的方法；(c)？包含这样的药物剂型和任选含另一治疗剂的第二药物剂型的药盒；(d)？制备这样的药物剂型的方法；和(e)？通过这样的方法制成的药物剂型。

Drugs covered by this patent

atrasentan-hydrochloride (ATRASENTAN HYDROCHLORIDE)

Patent Metadata

Patent number: CN105517541A
Jurisdiction: CN
Classification: —
Expires: 2016-04-20
Drug substance claim: No
Drug product claim: No
Assignee: AbbVie Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.